Proud to have our breakthrough breast cancer technology funded by Y Combinator – the Silicon Valley investor whose international status is second to none!
“Since 2005, Y Combinator has funded over 3,000 companies and worked with over 6,000 founders. Every 6 months over 10,000 companies apply to participate in our accelerator and we typically have a 1.5% – 2% acceptance rate.
In August 2021, Digistain has secured funding from Y Combinator. Money raised $125k”
Last week, we were proud to present two abstracts at the San Antonio Breast Cancer Symposium 2024. The first abstract showcased head-to-head data from Charing
We’re excited to announce that Digistain® has partnered Deloitte to drive adoption across Europe! This collaboration marks a significant step toward making breast cancer risk
We’re thrilled to announce that Digistain® is now available to over 60% of UK private patients, with reimbursement available though Bupa, WPA Health Insurance &
Supported by:
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.